Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25735320)

  • 1. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.
    Liu LY; Yu H; Bai JL; Zeng P; Miao DD; Chen F
    Asian Pac J Cancer Prev; 2015; 16(3):1001-6. PubMed ID: 25735320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting an overall survival benefit that is derived from progression-free survival.
    Broglio KR; Berry DA
    J Natl Cancer Inst; 2009 Dec; 101(23):1642-9. PubMed ID: 19903805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate endpoints for overall survival in lung cancer trials: a review.
    Fiteni F; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
    Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
    Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma.
    Nakashima K; Horita N; Nagai K; Manabe S; Murakami S; Ota E; Kaneko T
    J Thorac Oncol; 2016 Sep; 11(9):1574-85. PubMed ID: 27178983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
    Paoletti X; Oba K; Bang YJ; Bleiberg H; Boku N; Bouché O; Catalano P; Fuse N; Michiels S; Moehler M; Morita S; Ohashi Y; Ohtsu A; Roth A; Rougier P; Sakamoto J; Sargent D; Sasako M; Shitara K; Thuss-Patience P; Van Cutsem E; Burzykowski T; Buyse M;
    J Natl Cancer Inst; 2013 Nov; 105(21):1667-70. PubMed ID: 24108811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.